Vaccine-specific immune responses against Mycobacterium ulcerans infection in a low-dose murine challenge model
Kirstie M. Mangas,
Andrew H Buultjens,
Jessica L. Porter,
Sarah L. Baines,
Nicholas J Tobias,
Sacha J. Pidot,
Kylie M. Quinn,
David J. Price,
David C. Jackson,
Brendon Y. Chua,
Timothy P. Stinear
Posted 10 Oct 2019
bioRxiv DOI: 10.1101/800250 (published DOI: 10.1128/IAI.00753-19)
Posted 10 Oct 2019
The neglected tropical disease Buruli ulcer (BU) is an infection of subcutaneous tissue with Mycobacterium ulcerans. There is no effective BU vaccine. Here, we assessed an experimental prime-boost vaccine in a low-dose murine tail infection model. We used the enoyl-reductase (ER) domain of the M. ulcerans mycolactone polyketide synthases electrostatically coupled with a previously described TLR-2 agonist-based lipopeptide adjuvant, R4Pam2Cys. Mice were vaccinated and then challenged via tail inoculation with 14-20 colony forming units (CFU) of an engineered bioluminescent strain of M. ulcerans. Mice receiving either the experimental ER vaccine or Mycobacterium bovis Bacille Calmette-Guerin (BCG) were equally well protected, with both groups faring significantly better than non-vaccinated animals (p<0.05). A suite of 29 immune parameters were assessed in the mice at the end of the experimental period. Multivariate statistical approaches were then used to interrogate the immune response data to develop disease-prognostic models. High levels of IL-2 and low IFN-𝝲 produced in the spleen best predicted control of infection across all vaccine groups. Univariate logistic regression then revealed vaccine-specific profiles of protection. High titres of ER-specific IgG serum antibodies together with IL-2 and IL-4 in the draining lymph node (DLN) were associated with protection induced by the experimental ER vaccine. In contrast, high titres of IL-6, TNF-alpha;, IFN-gamma; and IL-10 in the DLN and low IFN-gamma; titres in the spleen were associated with protection following BCG vaccination. This study suggests an effective BU vaccine must induce localised, tissue-specific immune profiles with controlled inflammatory responses at the site of infection.
- Downloaded 156 times
- Download rankings, all-time:
- Site-wide: 76,022 out of 88,832
- In immunology: 2,125 out of 2,553
- Year to date:
- Site-wide: 64,944 out of 88,832
- Since beginning of last month:
- Site-wide: 58,511 out of 88,832
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!